GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Liabilities-to-Assets

Brii Biosciences (HKSE:02137) Liabilities-to-Assets : 0.04 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Brii Biosciences's Total Liabilities for the quarter that ended in Dec. 2023 was HK$137.67 Mil. Brii Biosciences's Total Assets for the quarter that ended in Dec. 2023 was HK$3,498.18 Mil. Therefore, Brii Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.04.


Brii Biosciences Liabilities-to-Assets Historical Data

The historical data trend for Brii Biosciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Liabilities-to-Assets Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
1.59 2.37 0.08 0.07 0.04

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only 0.08 0.09 0.07 0.04 0.04

Competitive Comparison of Brii Biosciences's Liabilities-to-Assets

For the Biotechnology subindustry, Brii Biosciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brii Biosciences's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brii Biosciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Brii Biosciences's Liabilities-to-Assets falls into.



Brii Biosciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Brii Biosciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=137.673/3498.179
=0.04

Brii Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=137.673/3498.179
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Brii Biosciences  (HKSE:02137) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Brii Biosciences Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Brii Biosciences's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Brii Biosciences (HKSE:02137) Business Description

Traded in Other Exchanges
Address
No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Executives
Hong Zhi 2101 Beneficial owner
Xyxy Holdings Ltd. 2201 Interest of corporation controlled by you
Booming Passion Limited 2101 Beneficial owner
Boyu Capital Fund Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd 2201 Interest of corporation controlled by you
Tong Xiaomeng 2201 Interest of corporation controlled by you
Boyu Group, Llc 2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Invesco Advisers, Inc. 2102 Investment manager
Ma Yun 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yf Bright Insight Limited 2101 Beneficial owner

Brii Biosciences (HKSE:02137) Headlines

No Headlines